VERICEL CORPORATION Payments to Acquire Debt Securities, Available-for-sale
VERICEL CORPORATION (VCEL) reported Payments to Acquire Debt Securities, Available-for-sale of $10.00 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2018-11-06
- 2018-09-30: Payments to Acquire Debt Securities, Available-for-sale 9 month $10.00M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 9 month |
|---|---|
| 2018-09-30 | $10.00M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |